TY - JOUR
T1 - Active surveillance in patients with a complete clinical response after neoadjuvant chemoradiotherapy for esophageal- and gastroesophageal junction cancer
AU - Huizer, Tamara J.
AU - Lagarde, Sjoerd M.
AU - Nuyttens, Joost J. M. E.
AU - Oudijk, Lindsey
AU - Spaander, Manon C. W.
AU - Valkema, Roelf
AU - Mostert, Bianca
AU - Wijnhoven, Bas P. L.
AU - SANO study group
N1 - Publisher Copyright:
© 2024 the author(s),
PY - 2024/11/7
Y1 - 2024/11/7
N2 - Neoadjuvant chemoradiotherapy in patients with esophageal- and gastroesophageal junction cancer induces tumor regression. In approximately one fourth of patients, this leads to a pathological complete response in the resection specimen. Hence, active surveillance may be an alternative strategy in patients without residual disease after neoadjuvant chemoradiotherapy. Previous studies have shown that the combination of esophagogastroduodenoscopy with bite-on-bite biopsies, endoscopic ultrasound with fine needle aspiration of suspected lymph nodes, and a PET-CT-scan can be considered adequate for the detection of residual disease. So far, it has been unclear whether active surveillance with surgery as needed is a safe treatment option and leads to non-inferior overall survival compared to standard esophagectomy after neoadjuvant chemoradiotherapy. This review will discuss the current status of active surveillance for esophageal and junctional cancer.
AB - Neoadjuvant chemoradiotherapy in patients with esophageal- and gastroesophageal junction cancer induces tumor regression. In approximately one fourth of patients, this leads to a pathological complete response in the resection specimen. Hence, active surveillance may be an alternative strategy in patients without residual disease after neoadjuvant chemoradiotherapy. Previous studies have shown that the combination of esophagogastroduodenoscopy with bite-on-bite biopsies, endoscopic ultrasound with fine needle aspiration of suspected lymph nodes, and a PET-CT-scan can be considered adequate for the detection of residual disease. So far, it has been unclear whether active surveillance with surgery as needed is a safe treatment option and leads to non-inferior overall survival compared to standard esophagectomy after neoadjuvant chemoradiotherapy. This review will discuss the current status of active surveillance for esophageal and junctional cancer.
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:001348244800001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1515/iss-2023-0010
DO - 10.1515/iss-2023-0010
M3 - Review article
SN - 2364-7485
JO - Innovative Surgical Sciences
JF - Innovative Surgical Sciences
ER -